Report Details:
15 Companies Covered
85 Pages
Pune, India, October 2018/MRFR Press Release/- Market Research Future published a half-cooked research report on the global sacroiliitis treatment market.
Market Highlights
Sacroiliitis is an inflammation located at the sacroiliac joints. it is a key symptom for several forms of inflammatory arthritis and is often the first to make itself identified in these diseases. Osteoarthritis, postural misalignment, and other mechanical issues are some of the conditions that can result in sacroiliac joint pain. The pain associated with sacroiliitis, along with joint changes can be viewed on a magnetic resonance imaging (MRI) is related to chronic inflammatory arthritis in the spine. Increasing incidences and prevalence of joint disorders, growing awareness among the population, increase in initiatives by government organizations and investment by private companies for research and development, rising elderly population all contributes to the growth of the sacroiliitis treatment market. However, factors such as the high cost of treatment procedures and rules and regulations are expected to restrict the market growth during the forecast period.
Segmentation
The global sacroiliitis treatment market has been segmented on the basis of type and end users. On the basis of type, the market has been classified as medications, joint injections, radiofrequency denervation, electrical stimulation, joint fusion. The medications are segmented into pain relievers, muscle relaxants, and TNF inhibitors. On the basis of end users, the market has been classified as hospitals, clinics, ambulatory care, home care, diagnostic centers, and others.
Access Report @ https://www.marketresearchfuture.com/reports/sacroiliitis-treatment-market-6590
Regional Analysis
The Americas is projected to lead the sacroiliitis treatment market in the forecast period. Increasing healthcare awareness, advancement in technology, medical tourism are some other factors that boost the growth of the market. According to WHO 9.6% of men and 18% of women aged above 60 have osteoarthritis worldwide.
The European market is expected to hold the second largest market share. The European market is projected to grow because of increase in elderly population, growing prevalence of accidents, and changing lifestyle in the region. This is expected to provide favorable backgrounds for the market to grow.
Asia-Pacific is projected to be the fastest growing region for the global sacroiliitis treatment market in 2018. Osteoarthritis is the second most common rheumatologic problem and is the most frequent joint disease with a prevalence of 22% to 39% in India. It is expected to witness profitable growth over the forecast period due to the existence of favorable healthcare schemes drafted by government agencies. Awareness programs and quality assurance of sacroiliitis treatment procedures have added importance in the developing economies of Korea, Taiwan, China, Sri Lanka, and India since the last few years. Osteo
The Middle East and Africa account for the least share due to stringent government policies and low per capita income. The strict regulatory environment in certain countries, the absence of technologically advanced instruments, interruptions and delays in hospitalization are major restraining factors for the global sacroiliitis treatment market.
Key Players
Some of the key players in the global sacroiliitis treatment market are Pfizer, Allergan, Ipsen Group, Teva Pharmaceuticals, Novartis, Johnson & Johnson, STEROID S.p.A., Sanofi, Bioventus, Salix Pharmaceuticals, Zimmer Holdings, Inc., Smith & Nephew Plc, and others.